Myrna Alexander
Cardiovascular Disease · Jackson, MSNPI 1285648063
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 201 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,577 and has fallen 89.2% since, to $171 in 2025.
Across 201 payments — averaging $22.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$840
- Abiomed$496
- Novartis$441
- Amgen$374
- Boehringer Ingelheim$317
- Cvrx, Inc.$261
- plus $2K from 19 others
What the payments were for
- Food & beverage$4,604100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 44 | $840 |
| Abiomed | 12 | $496 |
| Novartis | 27 | $441 |
| Amgen | 20 | $374 |
| Boehringer Ingelheim | 11 | $317 |
| Cvrx, Inc. | 2 | $261 |
| E.r. Squibb & Sons, L.L.C. | 16 | $211 |
| AstraZeneca | 8 | $202 |
| Boston Scientific | 2 | $151 |
| Johnson & Johnson | 10 | $150 |
| Lantheus Medical Imaging, Inc. | 3 | $143 |
| Irhythm Technologies, Inc. | 3 | $132 |
| Amarin Pharma, Inc. | 2 | $122 |
| Impulse Dynamics (USA) Inc. | 5 | $104 |
| Astellas Pharma US Inc | 5 | $101 |
| Atricure, Inc. | 2 | $97 |
| Actelion Pharmaceuticals US, Inc. | 3 | $83 |
| Gilead | 5 | $77 |
| Akcea Therapeutics, Inc. | 5 | $71 |
| Merck | 5 | $68 |
| Abbott | 3 | $65 |
| Bayer | 3 | $54 |
| Sanofi-aventis U.S. LLC | 2 | $24 |
| GE HealthCare | 2 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Barostim Neo System$261
- WATCHMAN Access System$141
- Impella$125
- Definity$120
- Vascepa$106
- FARXIGA$105
- ZIO Patch$102
- ELIQUIS$102
- JARDIANCE$100
How this compares
$4,618 in reported general payments places this provider in the 55th percentile of 144 cardiovascular disease providers in Mississippi.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 46 | $42,332 |
| JardianceEmpagliflozin | 36 | $39,169 |
| EliquisApixaban | 30 | $25,898 |
| FarxigaDapagliflozin Propanediol | 15 | $11,733 |
| Metoprolol Succinate | 105 | $1,353 |
| Isosorbide Dinitrate | 15 | $1,291 |
| Carvedilol | 93 | $924 |
| Valsartan | 17 | $863 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 17 | $841 |
| Rosuvastatin Calcium | 56 | $825 |
| Potassium Chloride | 40 | $752 |
| Torsemide | 14 | $679 |
| Atorvastatin Calcium | 59 | $537 |
| Furosemide | 74 | $498 |
| Amlodipine Besylate | 56 | $441 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $441 | $42,33246 claims |
| Boehringer IngelheimJardiance | $317 | $39,16936 claims |
| PfizerEliquis | $840 | $25,89830 claims |
| AstraZenecaFarxiga | $202 | $11,73315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 144 cardiovascular disease providers in Mississippi.
Other cardiovascular disease in Jackson
- Donny StokesJackson$207K
- James BenslerJackson$64K
- Michael HallJackson$54K
- Tahsin QarqishJackson$39K
- Christopher LatourJackson$33K
- Varun SardarJackson$31K
- Olurotimi BaderoJackson$20K
- Michael PaymentJackson$16K
- James HaysJackson$16K
- Douglas HarkinsJackson$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.